10th Oct 2014 11:10
LONDON (Alliance News) - Hikma Pharmaceuticals PLC said Friday that it will "work constructively for a positive outcome" in its litigation with Takeda Pharmaceuticals USA Inc, after a Delaware court granted Takeda's motion for a temporary restraining order on further distribution of Hikma's colchicine 0.6 milligram capsules.
The court has granted the restraining order whilst it considers Takeda's motion for a preliminary injunction.
Last Friday, Takeda filed a patent infringement law suit against Hikma's US generics business West-Ward Pharmaceutical Corp, Hikma Americas Inc and Hikma Pharmaceuticals regarding the capsules.
Hikma's colchicine capsules were approved by the US Food and Drug Administration on September 30. The product is used to treat prophylaxis in gout flares.
Hikma said the litigation will continue later this month.
Shares in Hikma are trading up 1.0% at 1,879.00 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals